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Sexually transmitted infections (STIs), formerly referred to as sexually 
transmitted diseases (STDs), remain a significant health concern in the United States.  
According to the Centers for Disease Control and Prevention (CDC; 2015), an estimated 
20 million newly diagnosed STIs are made each year and nearly half of the cases were 
attributed to individuals between the ages of 15-24 with an astounding $16 billion in 
associated healthcare costs.   
Urinary tract infections (UTIs) account for nearly five million primary care office 
visits each year (Johnson, 1996).  A urinary tract infection is the presence of bacterial 
infection within the urinary tract; it is generally classified by the site of microbial 
infection such as urine (bacteriuria), bladder (cystitis), or kidney (pyelonephritis; 
Foxman, 2002).  Diagnosis of either an STI or UTI can be difficult as presenting and 
associated symptoms such as complaints of urgency, frequency, and/or dysuria are 
similar in nature (Tomas, Getman, Donskey, & Hecker, 2015).  In addition, the results of 
a urinalysis (UA) might present overlapping abnormalities--most commonly pyuria and 
positive leukocyte esterase (Tomas et al., 2015).   
Less than 30% of reported chlamydial infections in women were symptomatic at 




that a prior sexual contact or partner was found to be infected or upon routine physical 
examination (Marrazzo et al., 1997).  Consequently, the number of patients with 
asymptomatic chlamydial infection results in delay in initiation of antibiotic therapy, 
prolonged course of infection, and increases the likelihood of disease transmission and 
probability of negative sequelae (Marrazzo et al., 1997).  Negative sequelae and health 
impact of untreated chlamydial infection include ectopic pregnancy, tubal infertility, 
chronic pelvic pain, and pelvic inflammatory disease (PID; Marrazzo et al., 1997). 
To enhance quality and consistency of primary care practice, the purpose of this 
Doctor of Nursing Practice capstone project was to develop an evidence-based guideline 
for improving diagnostic screening methods for diagnosis of chlamydial and gonorrheal 
infections in females who present with symptomatic complaints otherwise suggestive of a 
urinary tract infection.  Through utilization of two rounds of the Delphi method, 
healthcare providers in round one (six participants) and round two (four participants) 
provided their expert opinions regarding the necessity of a clinical practice guideline and 
factors that should be included within said guideline.  Recommendations included age 
parameters (all female patients between 15-25 years of age and/or female patients older 
than 25 years with an identified risk factor), screening questions in assessment of risk 
factors (past and recent sexual history), and symptom presentation indicative of either a 
UTI or STI (i.e., dysuria, urinary frequency, urinary urgency, suprapubic pain, and 
hematuria).  Implications of the Delphi method indicated the majority of participants felt 
routine STI testing was lacking at their respective organization, female patients were not 




availability of a clinical guideline would be effective in increasing STI testing rates for 
this patient population. 
Background information was collected not only through use of Delphi 
questionnaires but a retrospective study was conducted evaluating frequency of ICD-9 
and ICD-10 codes (CDC, 2017) for UTI from January 2013 through December 2016.  In 
addition, an in-depth chart review was performed investigating female patient visits for 
UTI complaints (i.e., urinary urgency, frequency, and/or dysuria) from October 2016 
through December 2016.  The Stetler (2001) model was used to translate the acquired 
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STATEMENT OF THE PROBLEM 
 
 
Background and Significance 
Sexually transmitted infections (STIs), formerly referred to as sexually 
transmitted diseases (STDs), remain a significant health concern in the United States.  
According to the Centers for Disease Control and Prevention (CDC; 2015), an estimated 
20 million newly diagnosed STIs are made each year; nearly half of the cases are 
attributed to individuals between the ages of 15-24 with an astounding $16 billion in 
associated healthcare costs.  Undiagnosed and unreported cases of STIs remain a 
substantial health concern; therefore, the magnitude of the problem might be greater than 
what published reports allude to (CDC, 2015).  In 2014, there was a considerable increase 
in nationally reported cases of chlamydia and gonorrhea from the prior year; 1,441,789 
new cases of chlamydia (2.8% increase) and 350,062 new cases of gonorrhea (5.1% 
increase) were diagnosed (CDC, 2015).   
Neisseria gonorrhoeae, a sexually transmitted bacterial infection, has been 
described dating back to the time of ancient Greeks.  Before the advent and knowledge of 
antibiotics, recommended treatment included cold baths, vinegar, almond milk, and violet 
oil.  During World War I, metallic compounds such as mercury, arsenic, bismuth, and 
radium were trialed as a cure.  Until the 1930s, antibiotics, specifically penicillin and 
sulfonamide antibiotics, were investigated as treatment and cure for gonorrheal infections 
2 
 
(Planned Parenthood, 2014).  Chlamydia trachomatis was first discovered in 1907 by 
Halberstaedter and von Prowazek (cited in Budai, 2007); it is a highly contagious gram-
negative bacterium most commonly passed through sexual intercourse.  Originally 
believed to be associated with gonorrhea, Halberstaedter and von Prowazek proved the 
existence of a new disease through examination of scrapings taken from an 
experimentally infected orangutan (Budai, 2007).  Current antibiotic treatment 
recommendations include use of azithromycin or doxycycline; both treatment regimens 
presently continue to have high cure rates (CDC, 2016). 
Although antibiotic regimens have effectively cured gonorrheal and chlamydial 
infections in the past, the emergence of antibiotic-resistant bacterium has prompted the 
New England Journal of Medicine to announce, “It is time to sound the alarm.  During 
the past 3 years, the wily gonococcus has become less susceptible to our last line of 
antimicrobial defense, threatening our ability to cure gonorrhea and prevent severe 
sequelae” (Bolan, Sparling, & Wasserheit, 2012, p. 485).  Various antibiotic classes 
previously successful in treatment of gonorrhea are no longer applicable; the rise of 
antibiotic-resistant gonorrhea has left only one class of antibiotics available-- 
cephalosporin antibiotics.  The World Health Organization (WHO; 2016) published new 
guidelines specifically for treatment of chlamydia and gonorrhea in response to the 
growing rate of antibiotic resistance partly attributed to overuse and misuse of antibiotics 
by physicians and other medical providers.  To combat this alarming trend, it is necessary 
for individuals with gonorrheal or chlamydial infections to be diagnosed early and 
medicated appropriately to prevent spread to others, avert reinfection with untreated 
partners, and reduce the propagation of antibiotic resistance.   
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Urinary tract infections (UTIs) account for nearly 5 million primary care office 
visits each year (Johnson, 1996).  Urinary tract infection is the presence of bacterial 
infection within the urinary tract and is generally classified by the site of microbial 
infection such as urine (bacteriuria), bladder (cystitis), or kidney (pyelonephritis; 
Foxman, 2002).  Although considered to be one of the most widespread and common 
bacterial infections, an accurate diagnosis can be challenging as patients might be 
asymptomatic at initial presentation.  Diagnosis is predicated upon symptoms identified 
by the patient and a positive urine culture.  However, diagnosis is often made in 
outpatient settings without a positive urine culture, leading to misdiagnoses and probable 
error estimates in true disease incidence (Foxman, 2002). 
Comparable to antibiotic resistance seen presently with chlamydia and gonorrhea 
treatment modalities, treatment regimens for UTIs are experiencing similar setbacks.  
Sanchez et al. (2016) performed a retrospective analysis investigating prevalence of 
antibiotic resistance from female patient data documented in 2003 compared with data 
collected in 2012.  Escherichia coli, the most common causative agent or pathogen 
identified in both 2003 and 2012 data analyses, has shown considerable differences in 
treatment susceptibility.  Urine samples taken from female patients in 2012 exhibited 
increased E. coli resistance to ciprofloxacin and trimethoprim-sulfamethoxazole, both 
therapy regimens highly effective in combating UTI in women in 2003 (Sanchez et al., 
2016).   
E. coli resistant antibiotics in treatment of UTI have also been found to 
significantly increase the workload of primary care practices as patients with resistant 
infections return for care for unrelieved or recurring symptoms.  Setting aside the 
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increased workload of healthcare providers, unsuccessful treatment of resistant UTI 
negatively affects an individual’s quality of life; patients unresponsive to treatment might 
experience symptoms twice as long as their counterparts with E. coli susceptible UTI 
(Butler et al., 2006).  Due to the trending nature and devastating consequences of 
ineffective antibiotic therapies, it is essential healthcare providers have the tools and 
resources necessary in appropriately diagnosing and treating disease processes that might 
otherwise be incurable in the future. 
Problem Statement 
 Diagnosis of either an STI or UTI can be difficult as presenting and associated 
symptoms such as complaints of urgency, frequency, and/or dysuria are similar in nature 
(Tomas, Getman, Donskey, & Hecker, 2015).  In addition, the results of a urinalysis (UA) 
might present overlapping abnormalities--most commonly, pyuria and positive leukocyte 
esterase (Tomas et al., 2015).  Less than 30% of reported chlamydial infections in women 
were symptomatic at time of diagnosis; most were detected through referral following 
required notification that a prior sexual contact or partner was found to be infected or 
upon routine physical examination (Marrazzo et al., 1997).  Consequentially, the number 
of patients with asymptomatic chlamydial infection resulted in delay in starting antibiotic 
therapy, prolonged course of infection, and increased probability of disease transmission 
and development of negative sequelae (Marrazzo et al., 1997).  The negative sequelae 
and health impact of untreated chlamydial infection included ectopic pregnancy, tubal 







Continued incidence of chlamydia and gonorrhea infections in the United States 
highlights the pervasiveness of misconceptions and lack of general knowledge regarding 
the need for effective and accurate STI testing and diagnosis; there is a need to aptly 
apply current evidence and knowledge into practice.  The Stetler (2001) model, originally 
developed in 1976, is an evidence-based utilization model to facilitate and simplify the 
transition of research into practice (see Figure 1).  The model provides a stepwise 
approach in facilitation of research in application of evidence-based practice (EBP) in 
five phases:  preparation, validation, evaluation/decision making, translation/application, 











• Phase I: Preparation.  Phase I or the preparatory phase identified the purpose 
of the capstone project based upon evidence suggesting a need to revise a 
current practice problem.  Additionally, this phase entailed development of 
the project foundation, project design, and Institutional Review Board (IRB) 
approval from both the practice organization and the University of Northern 
Colorado for project implementation.   
• Phase II: Validation.  Phase II encompassed the completion of a literature 
review.  A comprehensive literature review required assessment of all 
included evidence for applicability to the capstone’s purpose, credibility, 
and relevant value of implications for improved practice.   
• Phase III: Comparative Evaluation/Decision-Making.  Phase III included 
evaluation and feasibility of implementing a STI/UTI guideline within the 
designated primary care practice.  This phase was achieved through 
utilization of the Delphi method; a panel of experts comprised of medical 
doctors, nurse practitioners, and physician assistants was provided 
questionnaires regarding appropriate clinical parameters for successful 
development and critical information necessary to include within the clinical 
practice guideline.   
• Phase IV: Translation/Application.  Phase IV encompassed the development 
of the guideline (based upon information gathered from the Delphi 
questionnaire and literature review), advisement for implementation into 
practice, and physical implementation of the guideline at the intended 
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healthcare organization.  Due to time constraints for completion, this 
capstone project did not implement the guideline into practice. 
• Phase V: Evaluation.  The final phase appraises the outcomes attained after 
guideline implementation.  Evaluation of the guideline entails a review of 
outcome measures in relation to the guideline’s purpose.  In addition, it is 
during this phase that other parameters such as cost-benefit analysis and 
appraisal of any negative or unexpected outcomes should be addressed.  
This capstone project did not include a post-implementation evaluation of 
the guideline as the capstone project did not implement the guideline into 
practice.  
Literature Review 
As part of the foundational basis of this capstone project, a literature review was 
conducted investigating current UTI and STI evaluation, diagnostic and/or testing 
methods for differentiation, and consequences of misdiagnosis.  Electronic databases 
utilized were the Cumulative Index to Nursing and Allied Health Literature (CINAHL), 
Cochrane Database of Systematic Reviews, PubMed, and Google Scholar™.  Keywords 
employed were sexually transmitted infections, urinary tract infections, complications of 
sexually transmitted infections, misdiagnosis of sexually transmitted infections, and 
prevalence of urinary tract infections and sexually transmitted infections in primary care.  
An inclusion criterion was articles originally written in the English language and 
published between 1995 and 2016.  Study designs within this literature review included 
cross-sectional studies, retrospective cohort studies, observational cohort studies, 
systematic reviews, and meta-analyses.  
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Chlamydia and Gonorrhea Screening,  
Evaluation, and Diagnosis 
In the United States, Chlamydia trachomatis is the most prevalent STI with 
approximately 1,000,000 new cases reported each year (Wilbanks, Galbraith, & Geisler, 
2014).  Due to the frequent asymptomatic presentation of chlamydial infections in 
women, universal screening has been suggested as the most effective means of disease 
detection; however, the cost of such practice is unrealistic.  Therefore, it has been 
recommended that infection screening be selectively completed based upon 
organizational parameters or women be treated empirically using defined criteria 
addressing factors such as an individual’s age, sexual behavior, and/or symptomatic 
complaint(s) at time of visit (Marrazzo et al., 1997).  Cost-effectiveness analysis of no 
screening, selective screening, and universal screening of two separate cohorts--family 
planning clients and STD clients--for C. trachomatis found an approximate cost savings 
of $1,000 for each case prevented when using selective screening for individuals in both 
groups.  Additionally, results of the analysis indicated universal screening for family 
planning clients was more beneficial with an added $667 cost savings for every case 
prevented (Marrazzo et al., 1997).   
U.S. Preventive Services Task Force (USPSTF; 2016) has published eight 
recommendations for STI screening since 2000; each recommendation statement was 
founded upon a comprehensive systematic review.  With regard to chlamydia and 
gonorrhea screening, key clinical recommendation statements included  
(1) Screen sexually active, nonpregnant women at increased risk of 
chlamydia, gonorrhea, HIV, and syphilis infection. 
(2) Screen all pregnant women for hepatitis B, HIV, and syphilis; 




(3) Do not routinely screen women and men who are not at increased risk 
of sexually transmitted infections. (USPSTF, 2016, table 1) 
 
Increased risk is delineated by the individual’s age and sexual behavior.  Categorization 
of high-risk sexual behavior is defined as having a new sexual partner, multiple 
concurrent sexual partners, inconsistent use of protective barrier methods, engaging in 
sexual activity under the influence of drugs or alcohol, and/or exchanging sex acts for 
drugs or money.  Additional recommendations include universal screening for gonorrhea 
and chlamydia for all sexually active adolescents and women 25 years of age or younger 
(USPSTF, 2016).   
 Centers for Disease Control and Prevention (2016) screening recommendations 
for chlamydia and gonorrhea in women are similar to those made by the USPSTF (2016).  
Screening recommendations advise all sexually active women 25 years and younger or 
sexually active women older than 25 years regarded as higher-risk be tested for both 
chlamydia and gonorrhea annually.  Testing for C. trachomatis should be performed 
using swab specimens from the vagina or endocervix or use of first-catch urine.  Analysis 
of specimens from any of the accepted collection methods should be accomplished using 
nucleic acid amplification test (NAAT).  If an individual is found to be positive for either 
chlamydia or gonorrhea, it is recommended that testing be repeated in three months upon 
completion of antibiotic treatment.  Test-of-cure, generally performed three to four weeks 
after completing therapy, is only recommended if noncompliance with medication 
therapy is suspected, symptoms are persistent, or there are any concerns for reinfection 
(CDC, 2016). 
 In 2012, the USPSTF released updated recommendations for primary care 
practice screening of cervical cancer in women.  Prior to 2012, women were 
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recommended to initiate cervical cancer screening “within 3 years of the onset of sexual 
activity, followed by annual screening” (Bogler et al., 2015, p. e461).  Most recent 
recommendations stated screening should not be started until the age of 21 years with a 
papanicolaou (PAP) test completed every three years or every five years in combination 
with human papillomavirus (HPV) testing (USPSTF, 2012).  As many women choose not 
to have yearly STI testing completed unless done with their routine PAP examination, 
there was some concern regarding the negative relationship new recommendations might 
have on STI screening.  Bogler et al. (2015) conducted a retrospective study of five 
family practices and found screening for gonorrhea and chlamydia decreased by 50% 
since publication of the new guidelines in 2012.  Therefore, primary care practices and 
providers need to maximize other opportunities and patient care visits to ensure sexual 
health and STI screening are completed, especially for high-risk, young, female 
populations.           
 As already stated, consequences of untreated chlamydia and gonorrhea infection 
include infertility, ectopic pregnancy, and pelvic inflammatory disease.  To prevent these 
unwanted effects, it is essential timely and effective diagnosis be made.  Part of the 
difficulty in screening is lack of consensus regarding the most useful diagnostic tool and 
screening methods.  A systematic review by Watson et al. (2002) evaluated current lab 
tests available for their effectiveness and overall accuracy in diagnosing chlamydial 
infections in asymptomatic and sexually active individuals.  Nucleic acid amplification 
tests more accurately detected asymptomatic chlamydial infections when compared to 
non-culture tests.  Results of the meta-analysis also demonstrated NAATs could be 
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effectively performed using urine samples, which are simple, cost-effective, non-
invasive, and non-discriminatory (Watson et al., 2002). 
 Urine-based testing for diagnosis of chlamydia and gonorrhea using ligase chain 
reaction (LCR), a method of DNA amplification, has been found to be both sensitive and 
specific; ease and availability of urine-based testing allows for greater access for 
individuals seeking STD testing and effectively screens disease presence in asymptomatic 
individuals otherwise not pursuing healthcare services (Jones, Knaup, Hayes, & Stoner, 
2000).  Operation of this knowledge was applied in a community-based urine testing 
program in St. Louis, Missouri.  Of the 277 individuals in this study, greater than 90% of 
participants denied any genitourinary symptoms at time of screening and testing.  Nearly 
9% of urine tested returned positive for chlamydial or gonococcal infection.  In addition, 
approximately 75% of participants positive for gonorrhea were co-infected with 
chlamydia.  Surprisingly, infection did not correlate with number of sex partners, use of 
barrier methods at last sexual encounter, race or ethnicity, gender, or previous STD 
history (Jones et al., 2000); this information exemplifies the need for proactive screening, 
especially in individuals experiencing symptoms indicative of a UTI or STI.    
Co-Infection and Consequences of  
Chlamydia and Gonorrhea  
 Numerous studies have shown individuals with one STI were more likely and 
more susceptible to additional infections with other venereal diseases.  Of particular 
concern was co-infection with chlamydia and gonorrhea.  Conclusions drawn from the 
study by Sonkar et al. (2014) found a significant percentage of women presenting with 
complaint of vaginal discharge who subsequently had STI testing performed and lab 
results indicating co-infection(s) with C. trachomatis, N. gonorrhea, and/or T. vaginalis.  
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Similarly, results of a cross-sectional analysis performed by Kahn et al. (2005) observed 
a high co-infection rate of chlamydia and gonorrhea.  Adolescent males and females 
positive for gonorrhea had greater than a 50% co-infection rate with chlamydia. 
 According to Haggerty et al. (2010), approximately 8% of women in the United 
States during their lifetime have been given a diagnosis of PID.  Pelvic inflammatory 
disease is “thought to occur as microorganisms ascend from the lower genital tract, 
infecting and causing inflammation of the uterus, fallopian tubes, and ovaries” (Haggerty 
et al., 2010, p. S134).  One of the most common pathogens associated with development 
of PID is C. trachomatis.  Gynecologic and reproductive consequences of untreated PID 
include but are not limited to chronic pelvic pain, ectopic pregnancy, and infertility.  The 
timeframe between infection with a microorganism and development of PID is unclear.  
However, it was found up to 5% of women within a two-week period developed PID 
between diagnosis with chlamydia infection and onset of treatment (Haggerty et al., 
2010; Hook, Spitters, Reichart, Neumann, & Quinn, 1994). 
Screening and Diagnosis of Urinary  
Tract Infections 
 The urinary tract is composed of the kidneys, the ureters, the bladder, and the 
urethra.  An individual develops a UTI when bacteria ascend from the urethra and into 
the bladder.  A bladder infection, otherwise known as cystitis, is one of the most common 
bacterial infections; women typically report symptoms of burning or pain with urination 
(dysuria) and increased urinary frequency.  Similar to gonorrhea and chlamydia 
infections, women are disproportionately affected due to the female anatomic structure.   
 According to UpToDate® (2016), a UTI should be suspected in non-pregnant 
women who present with one or more of the following symptoms: frequency, urgency, 
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dysuria, hematuria, and/or suprapubic pain.  For diagnosis, UpToDate recommends a UA 
for evaluation of pyuria or the presence of pus in the urine.  Many primary care offices do 
not have in-house technology to perform a UA; therefore, use of dipstick urine strips are 
typically employed to detect the presence of nitrite and leukocyte esterase, indicative of a 
UTI.  UpToDate does not recommend routine urine cultures for women suspected of an 
uncomplicated UTI.  Urine cultures are suggested if the patient presents with symptoms 
not typical for a UTI, recurrent urine infection complaints within three months, or if 
symptoms persist after completion of antibiotic therapy.   
 Overreliance on UA and dipstick results and lack of confirmatory urine cultures in 
diagnosis might lend to over-diagnosis of UTIs.  As stated earlier, Tomas et al. (2015) 
found an abnormal UA result in patients with both UTIs and STIs after a two-month 
observational cohort study.  Of the 264 women included in the study, 92% of study 
participants had an abnormal UA, which was defined as “greater-than-trace leukocyte 
esterase level, a positive nitrite test result, or pyuria” (Tomas et al., 2015, p. 2689).   
Nearly 60% of women were diagnosed with a UTI and were prescribed treatment without 
a urine culture.  When study urine cultures were performed on each patient sample, 
culture results indicated over-diagnosis of UTI to be 52%.    
Sexually Transmitted Infection/Urinary  
Tract Infection Misdiagnosis 
Effective management of any disease requires accurate diagnosis; however, many 
challenges can arise when attempting to differentiate between diseases with similar 
symptomology.  In a study conducted by Huppert et al. (2007), the authors found 
discordant relationships between urinary symptoms and presence or absence of an STI; 
symptomology could not be used as a predictor for disease distinction.  Similarly, other 
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studies have shown only half of women given a singular diagnosis of a UTI at time of 
discharge had a subsequent confirmed urine culture; instead, up to 50% of those cultures 
indicated the presence of an STI (Berg, Benson, Haraszkiewicz, Grieb, & McDonald, 
1996; Tomas et al., 2015; Wilbanks et al., 2014). 
In a study conducted by Wilbanks et al. (2014), the authors retrospectively 
evaluated medical charts of female patients who presented to an emergency department 
(ED) with a primary complaint of dysuria and were later diagnosed with a UTI.  Of the 
280 women ultimately included in the study, results of the study revealed only a fraction 
(17%) of the females were asked questions regarding recent sexual history even when 
secondary complaints included vaginal bleeding, vaginal discharge, and pelvic pain.  
Sexually transmitted infection or chlamydia testing had been ordered or performed in 
merely 20% of this patient population; unexpectedly, only 30% of female patients with a 
prior history of chlamydial infection were tested again.  Although 67% of UAs performed 
were negative for presence of urinary nitrate, fewer than 7% of these samples were then 
sent for chlamydia testing.  Results of the study also showed less than half of the women 
appropriately diagnosed with chlamydia were prescribed the recommended treatment; 
most were prescribed medication used in UTI treatment and ineffective against 
chlamydia infection (Wilbanks et al., 2014). 
Additional studies illustrated 10% to 50% of women would test positive for an 
STI when presenting with typical UTI symptoms or might not have any symptoms at all 
(Mehta, Rothman, Kelen, Quinn, & Zenilman, 2001; Shapiro et al., 2005; Todd, Haase, & 
Stoner, 2001).  A prospective, observational cohort study completed by Shapiro et al. 
(2001) sought to determine and differentiate the incidence of UTIs and STIs when 
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considering associated positive and negative urine culture results, initial symptom 
presentation, and patient history.  Conclusions of the study found approximately 17% of 
female participants who presented with symptoms of a UTI had an STI instead; no 
statistically significant difference was found between positive or negative urine cultures.  
Results of analysis found the only variable predictive of a positive STI result was sexual 
history of greater than one sexual partner within the last 12 months; no other variables 
within the history or physical examination (including pelvic examination) could 
successfully differentiate between women who tested positive or negative for an STI 




















Q1 Within the outpatient setting, will the development of a STI/UTI urinalysis 
guideline reduce the incidence of misdiagnoses of urinary tract infections in 
patients with a sexually transmitted infection, more specifically infection 
with chlamydia or gonorrhea? 
 
Project Objectives 
Primary care practice settings are an essential component of healthcare practice; 
they provide an opportunity for both the medical provider and patient to improve upon an 
individual’s overall health and well-being.  Acute visits for complaints of urinary 
frequency, dysuria, and other symptoms suggestive of a UTI comprise a substantial 
portion of office visits each year.  However, as depicted by the literature review, 
screening for other microbial etiologies such as STIs are variable and inconsistent.  This 
lack of STI evaluation might lead to misdiagnosis and prescription of inadequate 
pharmaceutical therapy, predisposing the individual to gynecological and reproductive 
complications in the future.  In addition, due to the silent nature of chlamydia and 
gonorrhea, failure to eradicate these STIs potentiates the spread of these diseases to other 
individuals. 
Objectives for this capstone project entailed creation of a STI/UTI urinalysis 
clinical practice guideline to aide and support healthcare providers at Peak Health Family 
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Medicine in distinguishing between patients requiring more in-depth screening when 
presenting to the office with UTI complaints.  Objectives for this capstone project were 
as follows: 
1.  Gathered information regarding current screening and testing practices for 
female adolescents and women who presented to Peak Health Family 
Medicine with UTI complaints. 
• Performed a retrospective study evaluating frequency of International 
Classification of Diseases (ICD)-9 and ICD-10 diagnosis codes for 
UTI from January 2013 through December 2016 (CDC, 2017). 
• Performed an in-depth retrospective review of female patient charts 
with a chief complaint of UTI symptoms (i.e., urgency, frequency, 
and/or dysuria). 
• A panel of medical personnel was questioned regarding their expert 
opinion and knowledge regarding creation of said guideline.  
• Increased awareness of current prevalence of chlamydia and gonorrhea 
infection in primary/outpatient care. 
• Increased knowledge regarding benefits of STI testing with patients 
presenting with UTI complaints. 
2.   Developed a STI/UTI urinalysis guideline for medical providers in provision 
of evaluation, screening, testing, and treatment of female patients who 
presented with UTI complaints. 
• Early diagnosis of STI infection. 
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• Decreased or prevented transmission rates of chlamydia and 
gonorrhea. 
• Reduced probability of negative sequelae from untreated chlamydia 
and gonorrhea infections. 
3.   Planned for implementation of the clinical practice guideline.  However, as 
previously stated, this capstone author did not physically implement the 
clinical practice guideline due to time constraints. 
Project Plan 
Setting and Resources 
 The setting for this capstone project took place at Peak Health Family Medicine.  
Peak Health Family Medicine, which opened in 2012, is a private primary care practice 
located in Littleton, Colorado.  The office is composed of one medical doctor (MD), two 
physician assistants (PA), and one nurse practitioner (NP).  Care provided at this facility 
includes proactive preventative care, comprehensive women’s and men’s health, pediatric 
and adolescent care, and medical weight loss.  Retrospective evaluation of frequency of 
ICD-9 and ICD-10 diagnoses (CDC, 2017) for UTI was gathered from Peak Health 
Family Medicine’s electronic medical record (EMR) from January 2013 through 
December 2016.  In addition, an in-depth chart review was performed investigating 
female patient visits for UTI complaints (i.e., urinary urgency, frequency, and/or dysuria) 
from October 2016 through December 2016. 
 Based upon information gathered from the literature review, it was evident family 
practice offices have played a role in the continued incidence and prevalence of 
chlamydia and gonorrheal infections in the United States.  Due to similar presentations of 
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urinary complaints for both UTI and STIs, a STI/UTI urinalysis clinical practice 
guideline was necessary to improve patient care and decrease the trend of undiagnosed 
and ineffectively treated disease processes.  The impact of STI is non-discriminatory; the 
effects can be seen in every gender, race, and socioeconomic category.   
 Financial resources necessary for successful completion of this capstone project 
were minimal as this capstone project was in fulfillment of the Doctor of Nursing 
Practice degree as outlined by the University of Northern Colorado Graduate School.  
The majority of labor required was performed by the student with one exception.  Upon 
completion of both portions of the retrospective study, statistical analysis of the data was 
completed in conjunction with Kathleen Dunemn, Ph.D., APRN, CNM-BC, and Research 
Advisor for this capstone project.  Miscellaneous budgetary demands included cost to 
print materials.  Resource support was provided by Peak Health Family Medicine through 
use of their EMR--an integral part of the retrospective study. 
Sample 
 The population under investigation for the retrospective portion of this capstone 
project was women between the ages of 15-65 who presented to Peak Health Family 
Medicine with a chief complaint indicative of a UTI such as complaint of dysuria, urinary 
frequency, and/or urinary urgency between October 2016 and December 2016.  
Frequency and/or prevalence of ICD-9 and ICD-10 diagnosis (CDC, 2017) of urinary 





Timeline of Project 
• Fall 2016—Approval of phenomenon of interest 
• January 2017 to February/March 2017 
o Institutional Review Board approval was obtained from the University 
of Northern Colorado’s Institutional Review Board (see Appendix A).  
A statement of mutual agreement was also signed between Peak 
Health Family Medicine and the University of Northern Colorado (see 
Appendix B). 
o Defense of first three chapters of capstone project 
• April 2017 
o Retrospective study completed from evaluation of patient charts 
(October 2016-December 2016) and ICD-9 and ICD-10 diagnoses 
analysis (2013-2016) 
o Initial Delphi questionnaire sent to providers (see Appendix C) along 
with informed consent to participate in human research (see Appendix 
D) 
• May 2017 
o Development of clinical practice guideline 
o Second Delphi questionnaire sent to providers (see Appendix E) 





• June 2017 
o Submission of capstone project to project committee 
o Final defense of capstone project 
Design 
 Phase one.  The first step in phase one of the EBP project entailed the completion 
of a thorough literature review.  Upon completion of the literature review, it was evident 
there was a significant need for the development of a STI/UTI guideline to assist 
providers in identifying individuals who would be deemed high-risk or have increased 
susceptibility in contracting an STI such as chlamydia and/or gonorrhea.  The second step 
in phase one was the conduction of a retrospective review of patient charts; each 
identified chart was evaluated for initial patient complaint(s), procedures conducted, 
results of procedures, diagnoses, and whether the patient returned to care after initial 
treatment of a UTI and later identified as having an STI. 
 Phase two.  Phase two was the development of a clinical practice guideline; the 
Delphi method was utilized to build said practice guideline.  The development of the 
practice guideline included collaboration with experts to identify necessary components 
that would need to be included within the guideline such as laboratory tests and questions 
to ask the patient when presenting with specific complaints associated with typical 
urinary tract infections.  Experts included a physician, physician assistants, and nurse 
practitioners involved in the diagnosis, management, and prevention of sexually 
transmitted infections within the community.  Administration of the initial Delphi 
questionnaire spanned beyond the medical providers at Peak Health Family Medicine to 
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include healthcare providers at other organizations such as Planned Parenthood and 
Kaiser Permanente. 
 Phase three.  Phase three was the plan for implementation.  The plan for 
implementation entailed distribution of the clinical guideline to stakeholders at Peak 
Health Family Medicine to review and modify.  A second Delphi questionnaire was then 
administered to the medical providers at Peak Health Family Medicine for evaluation of 
the guideline as the clinical guideline was specifically tailored for their primary care 
private practice (see Appendix E).  During this phase, the tools for measurement were 
evaluated such as the most effective means with which to identify or quantify the 
presence of proper utilization of the clinical guideline in addition to evaluating whether 
the clinical guideline achieved the stated objectives.   
 Phase four.  Phase four would have included the physical implementation of the 
clinical guideline in practice.  Phase four was not completed during this capstone project.  
However, the guideline was made available to Peak Health Family Medicine to 














EVALUATION OF PLAN 
 
 
 To enhance quality and consistency of primary care practice, the purpose of this 
DNP capstone project was to develop an evidence-based guideline for improved 
diagnostic screening methods for diagnosing chlamydial and gonorrheal infections in 
females who presented with symptomatic complaints otherwise suggestive of a urinary 
tract infection.  Peak Health Family Medicine did not have a guideline in place to 
adequately differentiate between women who might have a common UTI versus an STI.  
As evidenced by the literature review, negative sequelae of undiagnosed and untreated 
STIs are severe and, unfortunately, fairly widespread.  Three objectives were 
accomplished for this capstone project. 
Objective One 
Objective one was to gather past information regarding screening, testing, and 
diagnostic practices for female patients who presented to Peak Health Family Medicine 
with symptoms typical of a UTI between October 2016 and December 2016.  The first 
objective was accomplished via two methods.  A retrospective study was conducted 
investigating patient charts, specifically charts for female patient visits with a chief 
complaint of urgency, frequency, dysuria, and/or UTI.  Analysis of the data revealed the 
number or percentage of visits concerning UTI complaints and the relative influence a 
guideline could have on daily practice at Peak Health Family Medicine.  Secondly, the 
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Delphi method or survey was utilized to garner general knowledge, suggestions, and 
practice from a panel of medical experts in development of the clinical practice guideline. 
Objective Two 
Objective two was the development of the clinical practice guideline for 
evaluation, screening, testing, and treatment of female patients at Peak Health Family 
Medicine who present with complaints typical of a UTI.  Using information gathered 
from the retrospective patient study and Delphi questionnaire, the foundational basis of 
the STI/UTI urinalysis guideline was founded upon recommendations from the USPSTF 
(2016) and medical provider suggestions regarding information that should be included 
within the guideline.  During creation of the guideline, each provider who completed the 
Delphi survey was asked to provide expert opinion on the need for implementing such a 
guideline, feasibility of use of said guideline, and applicability of use in day-to-day 
practice.  Once the guideline had been created, a second Delphi questionnaire was sent 
regarding evaluation of the guideline in relation to the aforementioned criteria. 
Objective Three 
The third objective of this capstone project was the plan for implementing the 
clinical guideline into practice.  Implementation of this clinical guideline at Peak Health 
Family Medicine was not part of this completed capstone project.  However, if Peak 
Health Family Medicine chooses to implement this guideline in the future, it would be 
highly recommended they evaluate the success of the guideline through one or more of 
the following measures.  First, it would be prudent to conduct another retrospective chart 
study comparing results from pre- and post-guideline implementation for screening and 
testing of female patients with urinary complaints.  Second, it would also be beneficial to 
26 
 
examine the percentage of STI diagnoses made prior to and after the implementation of 
the clinical practice guideline to analyze any statistical differences.  Finally, after a trial 
period, any revisions should be made such as inclusion or expansion of criteria including 













RESULTS AND OUTCOME STATEMENTS 
 
 
 This DNP capstone project sought to address the current problem regarding 
misdiagnosis of STIs and UTIs in primary care practice--more specifically, misdiagnosis 
of chlamydia and gonorrheal infections in female patients with symptom complaints 
otherwise indicative of a UTI.  The first objective of this capstone project was to collect 
information concerning screening, testing, and diagnostic practices for female patients 15 
through 65 years of age who visited Peak Health Family Medicine with a chief complaint 
suggestive of a UTI.  Objective two was development of a STI/UTI urinalysis clinical 
practice guideline to assist medical providers at Peak Health Family Medicine in 
evaluation, screening, testing, and treatment of female patients who presented with 
symptoms typical of a UTI who might otherwise have an undiagnosed STI.  The third and 
final objective was a plan for implementing and evaluating the STI/UTI Urinalysis 
Clinical Practice Guideline in practice.  Physical implementation of the guideline was not 
a component of the final capstone project; therefore, evaluation of said guideline post 
implementation was not discussed nor included.  However, recommendations regarding 







 Objective one was achieved through completion of a two-part retrospective study 
that entailed a three-month patient chart review and a four-year ICD-9 and ICD-10 
diagnoses analysis (CDC, 2017).  Both portions of this study were conducted utilizing the 
EMR at Peak Health Family Medicine, which makes use of an eMDs platform or system.  
For the first portion of the study, female patient charts from October 1, 2016 through 
December 31, 2016 were assessed for specific parameters; patients were included in the 
study if they met the following criteria: (a) the patient was female, (b) between 15 and 65 
years of age, and (c) chief complaint was suggestive of a UTI.  The second step or part of 
the study was completion of a four-year retrospective analysis (January 1, 2013 through 
December 31, 2016) evaluating overall frequency of documented ICD-9 and ICD-10 
diagnoses codes for UTI, UTI-specific symptomology, chlamydia, and/or gonorrhea.  
Due to time and additional processes required in evaluation of individual patient charts, it 
was not feasible to conduct a four-year patient chart review.  To truly meet objective one, 
however, it was necessary for a chart review to be included.  For this reason, a chart 
review with a condensed timeframe provided similar data and related insight in achieving 
original outlined goals.        
 Part One: Materials and Methods 
 For the retrospective chart review, the group under investigation was a 
convenience sample using Peak Health Family Medicine’s EMR.  Patients were included 
if all of the aforementioned criteria were met.  If a patient’s chart did not meet each of the 
specified criteria, the chart was automatically excluded from the study.  As this portion of 
the study did not use human subjects and no identifying patient information was 
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collected, no informed consent was required.  The following capstone project and all 
included studies were given Institutional Review Board approval by the University of 
Northern Colorado (see Appendix A). 
 The initial step in conducting the retrospective chart review was identifying all 
potential subjects: every female 15 to 65 years old between October 1, 2016 and 
December 31, 2016.  The age parameter was established to incorporate the main 
screening recommendations from both the CDC (2016) and USPSTF (2016) for 
chlamydia and gonorrhea.  Based upon knowledge that infection rates of chlamydia and 
gonorrhea are highest in females 15-25 years of age, additional data analysis was 
performed specifically investigating this patient demographic.  After application of age 
and gender parameters, each of the chart’s chief complaint(s) was examined and assessed 
for symptom complaints characteristic for a UTI or if the term UTI Symptoms was 
explicitly noted.  Within this EMR platform, supplementary symptoms and added 
complaints were incorporated within the umbrella term of UTI symptoms; therefore, 
complaints of flank pain, abdominal pain, hematuria, nausea, urinary frequency, dysuria, 
urinary urgency, dyspareunia, and chills were all included.   
 After a chart had met all inclusionary criteria listed above, the second step 
included review of the chart for results of urinalysis (if one had been performed), positive 
or negative urine culture results (if one had been sent), diagnosis/diagnoses of visit, and 
associated treatment.  The third and final aspect of the chart review was evaluation for 
testing of either chlamydia, gonorrhea and/or both chlamydia and gonorrhea principally 




 Part One: Results  
 Results of the study revealed Peak Health Family Medicine provided care to 41 
female patients (see Appendix F) between October 1, 2016 and December 31, 2016 
whose documented chief complaint was indicative of a UTI and were between 15 and 65 
years of age.  Of the 41 patient visits, eight visits occurred in October, 15 in November, 
and 18 in December.  The most frequently documented chief complaint was UTI 
symptoms in 73.2% (30/41) of patient charts.  In addition to complaint of UTI symptoms, 
other specific complaints included flank pain, abdominal pain, hematuria, nausea, urinary 
frequency, urinary urgency, dysuria, chills, dyspareunia, and hesitancy.  In conjunction 
with UTI complaints, four patient charts (9.8%; 4/41) listed other gynecological 
complaints such as vaginal irritation, vaginal discharge, vaginal itching, and/or vaginal 
odor.  
 A urinalysis was ordered and performed 95.1% (39/41) of the time; one patient 
was excluded from a UA due to having taken AZO while there was no notation for lack 
of UA being performed on the second patient.  Of the 39 urinalyses performed, 30.8% 
(12/39) were interpreted as a negative UA result.  A UA result was positive if any of the 
following findings were documented: blood in urine, leukocytes, protein urine, nitrite, 
ketones, and glucose.  A urine culture was sent for 35 of the 41 patients (85.4%); 
subsequent culture findings were 48.6% (17/35) of cultures were positive for a UTI and 
51.4% (18/35) were negative for a UTI.  Relatedly, microorganisms grown in positive 
cultures included Escherichia coli (76.5%; 13/17), Group B Streptococcus (11.8%; 2/17), 
and Klebsiella pneumoniae (11.8%; 2/17). 
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 One patient (2.4%; 1/41) was tested for chlamydia and gonorrhea within the 
three-month chart review.  When exclusively looking at patients between 15 and 25 years 
of age, seven patients were seen between October 1, 2016 and December 31, 2016, thus 
increasing the testing percentage for chlamydia and gonorrhea to 14.3% (1/7).  All seven 
patients had a UA performed with 85.7% (6/7) of the urine samples sent for culture.  
Results of urinalysis and urine culture were positive for 57.1% (4/7) and 33.3% (2/6) of 
the samples, respectively.  Antibiotic therapy was prescribed for 71.4% (5/7) of this 
patient population. 
Part One: Outcome Statements 
Over the course of three months, Peak Health Family Medicine had 41 female 
patient visits for UTI related care; however, there appeared to be a discrepancy in number 
of patient visits for the month of October (8/41) when compared to November (15/41) 
and December (18/41).  It was found the practice was closed for more days in the month 
of October than in November or December for a team-building vacation in Mexico.  The 
additional closure time could account for the decreased number of patient visits during 
this month. 
 Although the EMR utilized at Peak Health Family Medicine enabled the umbrella 
term of UTI symptoms to be chosen as the patient’s chief complaint, it offered the user 
the ability to add additional symptom complaints.  As discussed by Tomas et al. (2015), 
the challenge in STI and UTI diagnosis is the overlapping symptomology such as 
complaint of urgency, frequency, and/or dysuria.  Results of the chart review supported 
this finding; urinary frequency (48.8%; 20/41), urinary urgency (43.9%; 18/41), and 
dysuria (46.3%; 19/41) were complaints verbalized by nearly half of all patients.   
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 Providers consistently ordered and performed a urinalysis for patients.  If the 
patient who had taken AZO was included, the percentage of ordered UA for UTI 
complaints would increase to 97.8%.  Urine cultures were also routinely sent.  Standard 
practice at this organization was for most, if not all urine samples be sent for culture and 
sensitivity testing regardless of the UA result.  Subsequent urine culture findings 
indicated more than half (51.4%; 18/35) of urine cultures sent were negative for growth.  
The high percentage of negative urine culture results aligned with other study findings 
that showed only about half of UTI diagnoses were confirmed with a positive urine 
culture (Berg et al., 1996; Tomas et al., 2015; Wilbanks et al., 2014).   
 The percentage of patients tested for chlamydia and gonorrhea was trivial 
regardless of whether the author categorized female patients into the 15- to 25-year-old 
age range (14.3%) or expanded the age range to 15 to 65 years of age (2.4%).  Of 
particular concern was the small percentage of female patients 15 to 25 years of age who 
had chlamydia and gonorrhea testing completed.  According to published screening 
recommendations made by the CDC (2016) and USPSTF (2016), females within this age 
group, if sexually active, should have yearly STI (chlamydia and gonorrhea) testing 
completed.  For the seven females 15 to 25 years of age included in the study, 57.1% 
(4/6) of UA results were positive; however, only 33.3% (2/6) of urine culture results were 
positive and confirmed the presence of a UTI.  Unfortunately, the corresponding 
percentage of negative urine cultures (66.7%; 4/6) might represent potential undiagnosed 





Part Two: Materials and Methods 
 Similar to the chart review, the second part of the retrospective study utilized the 
EMR in completion of a four-year ICD-9 and ICD-10 (CDC, 2017) diagnoses analysis.  
Frequency of every diagnosis/diagnoses made by each provider for all patient visits at 
Peak Health Family Medicine was documented from January 1, 2013 through December 
31, 2016.  Both ICD-9 and ICD-10 codes were included in this capstone project as Peak 
Health Family Medicine transitioned from ICD-9 to ICD-10 coding in 2015.  Resultant 
data from 2015 included both ICD-9 and ICD-10 codes, whereas all other years only 
comprised either ICD-9 or ICD-10 diagnoses. 
 Diagnosis codes included in the study were as follows: acute cystitis; dysuria; 
urinary frequency; urinary tract infection; urgency of urination; acute pyelonephritis; 
hematuria, unspecified; gross hematuria; cystitis; acute cystitis without hematuria; acute 
cystitis with hematuria; cystitis unspecified without hematuria; cystitis unspecified with 
hematuria; and gonococcal infection of lower genitourinary tract, unspecified (see Table 
1).  Of note, not every ICD-9 code had an associated ICD-10 code and vice versa (CDC, 
2017).  All healthcare organizations were required to transition from use of ICD-9 to 
ICD-10 coding structure by October 1, 2015.  The ICD-10 was developed to improve 
data quality for purposes of monitoring public health conditions, increasing access to data 
for epidemiological research, enhancing clinical decision making, establishing 






Table 1  
International Classification of Diseases Diagnosis Codes 
Diagnosis ICD-9 Code ICD-10 Code 
Acute cystitis 595  
Dysuria 788.1 R30.0 
Urinary frequency 788.41  
Urinary tract infection 599 N39.0 
Urgency of urination 788.63 R39.15 
Acute pyelonephritis 590.1 N10 
Hematuria, unspecified 599.7 R31.9 
Gross hematuria 599.71 R31.0 
Cystitis 595.9  
Acute cystitis without hematuria  N30.00 
Acute cystitis with hematuria  N30.01 








Gonococcal infection of lower 
genitourinary tract, unspecified 
 A54.0 
    
 
     
Part Two: Results 
 Results of the retrospective analysis demonstrated an upward trend from January 
1, 2013 to December 31, 2016 in number of UTI diagnoses documented and UTI 
associated symptoms (see Figure 2).  Incidence of all applicable diagnoses as a whole 
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(excluding diagnosis code A54.0) revealed that 134 UTI related diagnoses were rendered 
in 2013, 142 in 2014, 217 in 2015, and 222 in 2016.  Acute cystitis was the most frequent 
diagnosis made every year during this study; the diagnosis accounted for 48.5% in 2013, 
47.9% in 2014, 44.7% in 2015, and 50.5% in 2016 of UTI-related diagnoses for each 
respective year.  Due to increased specificity requirements in ICD-10 coding for 
diagnosis of acute cystitis, diagnosis codes N30.0 (acute cystitis without hematuria), 
N30.01 (acute cystitis with hematuria), N30.90 (cystitis, unspecified without hematuria), 
and N30.91 (cystitis, unspecified with hematuria) were all factored into the total number 
of acute cystitis diagnoses to correlate with the more indiscriminate ICD-9 code 595 
(CDC, 2017).  Zero chlamydia diagnoses were made during this four year review.  
Diagnosis of “Gonococcal infection of lower genitourinary tract, unspecified” was 
documented once in 2015.  For detailed differentiation of ICD-9 and/or ICD-10 codes for 




Figure 2.  International classification of diseases diagnosis codes related to urinary tract 
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Figure 3.  Differentiation of international classification of diseases-9 urinary tract 





Figure 4.  Differentiation of international classification of diseases-9 urinary tract 
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Figure 5.  Differentiation of international classification of diseases-9 urinary tract 




Figure 6.  Differentiation of international classification of diseases-10 urinary tract 
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Figure 7.  Differentiation of international classification of diseases-10 urinary tract 




Part Two: Outcome Statements 
 Expectation for any growing practice is the number of patient visits or encounters 
would increase accordingly; thus, the upward trend in number of UTI diagnoses 
documented from January 1, 2013 to December 31, 2016 was anticipated.  Although the 
author did not foresee chlamydia and gonorrhea to be a commonly made diagnosis at this 
practice, results of the study were unexpected.  Over the course of four years, infection 
with chlamydia was documented zero times, whereas diagnosis of gonococcal infection 
was documented once. 
 Peak Health Family Medicine is located in Jefferson County.  According to 
Colorado Youth Matter (2015), chlamydia rate (per 100,000) and gonorrhea rate (per 
100,000) in Jefferson County was 917.95 and 79.69, respectively, for adolescents 15- to 










2016 ICD-10 UTI DIAGNOSES
Dysuria
Acute Cystitis without hematuria
Acute Cystitis with hematuria





Cystitis, unspecified without hematuria
Cystitis, unspecified with hematuria
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was 534,543 with 50% of the population female and approximately 12.5% of this subset 
15 to 24 years of age (Suburban Stats, 2015).  Given the infection rate for both chlamydia 
and gonorrhea in Jefferson County, it is highly probable/highly likely that diagnosis of 
either of these STIs was missed. 
 Objective one (Part One and Part Two) required application of both Phase I 
(Preparation) and Phase II (Validation) of the Stetler (2001) model.  Results from the 
retrospective study provided evidence indicating modifications were needed in current 
STI and UTI management and a practice problem did exist.  Knowledge acquired from 
the completed literature review provided the author with an explanation and background 
information for study findings and reiterated the relevant value and credibility of a 
clinical guideline.                    
Objective Two 
 Objective two was creation of the STI/UTI Urinalysis Clinical Practice Guideline 
(see Appendix G).  Objective two required incorporation and utilization of Phases I-IV 
within the theoretical framework of the Stetler (2001) model; Preparation (Phase I), 
Validation (Phase II), Comparative Evaluation/Decision-Making (Phase III), and 
Translation/Application (Phase IV) were all applied in achieving this objective.  Round 
one of the Delphi questionnaire was employed in developing the guideline, whereas 
round two of the Delphi questionnaire was used to garner expert opinion regarding any 
identified weaknesses and/or suggested changes in the clinical guideline.   
Rounds One and Two of the Delphi  
Questionnaire 
 Round one of the Delphi questionnaire was developed using evidence-based 
information collected from the literature review completed for this DNP capstone project 
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in addition to published screening and testing guidelines for chlamydia and gonorrhea 
from both the CDC (2016) and USPSTF (2016).  The purpose of the initial Delphi 
questionnaire was to assemble expert opinions regarding the need to implement an 
STI/UTI urinalysis clinical practice guideline, potential utility of said guideline, 
feasibility of use, and applicability of use in routine practice.  Additionally, round one 
incorporated questions regarding study participants’ adherence to current practices in 
screening, testing, and diagnosis of UTIs in female patients as advised by UpToDate 
(2016).  Informed consent (see Appendix D) was provided with each round of the 
questionnaire; consent for participation was implied with completion and return of the 
completed questionnaire to the author.  Round one of the Delphi questionnaire was 
available to participants for completion for 10 days (see Appendix C) while round two 
was available for seven days (see Appendix E).  Two rounds of the Delphi method were 
ultimately employed and required to obtain essential information in creating and 
completing the STI/UTI Urinalysis Clinical Practice Guideline (see Appendix G).     
Participants 
 Experts or participants for this DNP project were composed of nurse practitioners, 
physician assistants, and physicians.  Providers from a variety of disciplines and Denver 
Metro locations were requested to participate in round one.  Round one of the Delphi 
questionnaire resulted in a 75% (6/8) response rate with six respondents composed of one 
physician, three nurse practitioners, and two physician assistants.  Disciplines represented 
included urgent care, OB/GYN, and family medicine (see Table 2).  Participation in 
round two was limited to medical providers employed at Peak Health Family Medicine as 
the guideline was created specifically for their organization.  Round two generated a 
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100% (4/4) response rate with all four medical providers at the organization completing 
the second Delphi questionnaire.  Peak Health Family Medicine is comprised of one 
physician, two physician assistants, and one nurse practitioner. 
       
Table 2   
Demographics of Participants in Round One of Delphi Questionnaire 
Participant Number Career Title/Role Discipline Denver Metro Area 
Participant #1 NP Urgent Care North 
Participant #2 NP OB/GYN South 
Participant #3 PA Family Medicine South 
Participant #4 MD Family Medicine South 
Participant #5 NP Family Medicine South 





 Collection of data occurred between April 2017 and May 2017.  Questions from 
round one were intended to gather expert opinions regarding agreement with and 
adherence to current STI recommendations from the CDC (2016) and USPSTF (2016).  
In addition, questions from round one were structured to garner attitudes toward need for 
a guideline in differentiation between STIs and UTIs and suggestions regarding 
inclusionary components of said guideline.  Rounds one and two of the Delphi 
questionnaires were sent through e-mail.  The general purpose of round two was to attain 
provider consensus surrounding each aspect of the proposed guideline in preparation of 
the final version of the guideline for implementation.  Consensus, as defined by this DNP 
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project, was a statistical score of 0.70 or greater for each question, representing majority 
agreement among participants for each component of the clinical guideline.     
Results and Outcome Statements:  
Round One Delphi Questionnaire 
 
 Round one of the Delphi questionnaire was composed of 11 questions.  In 
question six, 66.7% (4/6) of participants felt patients were not being adequately screened 
for STI(s) at their organization.  Analogous to participant response to question six, 66.7% 
(4/6) of healthcare providers did not feel patients were routinely screened for STI(s) at 
their organization when presenting with a chief complaint indicative of a UTI (question 
seven).  Although 33.3% (2/6) of study participants felt that patients were being 
adequately screened for STI(s) and routinely screened for STI(s) when a female presents 
with UTI symptoms at their organization, the same comment was made to both questions: 
“In OB/GYN, but not always in primary care or peds.”  Based upon responses from 
questions six and seven, it was apparent providers were aware that STI screening might 
be insufficient and opportunities were being missed or overlooked in addressing sexual 
health.   
 As a follow-up to question seven, question eight (“How often do you believe 
female patients are being tested at your organization for chlamydia and gonorrhea 
infections when presenting with a chief complaint otherwise indicative of a UTI?”), 
16.7% (1/6) responded 90% to 100%, 16.7% (1/6) responded 70% to 79%, and 66.7% 
(4/6) responded less than 20%.  When asked if screening for chlamydia and gonorrhea 
would occur more frequently if a clinical guideline was made available to each of the 
healthcare provider’s respective organization, 100% (6/6) indicated a guideline would 
increase screening for these diseases. 
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 Question 10 provided a list of potential criteria to be included within the STI/UTI 
Urinalysis Clinical Practice Guideline in assessment of known risk factors for infection 
with either chlamydia or gonorrhea.  Participants were asked to check all criteria that 
should be covered within the guideline; criteria as well as percentages included: 
• Age (66.7%; 4/6) 
• Current form of contraception (33.3%; 2/6) 
• Number of past sexual partners within the past year (66.7%;4/6) 
• New sexual partner (83.3%; 5/6) 
• History of prior sexually transmitted infection(s; 66.7%; 4/6) 
If yes, did you receive a test of cure? 
• Substance use (alcohol, tobacco, recreational drugs; 33.3%; 2/6) 
• Sex in exchange for money or drugs (66.7%; 4/6) 
• Current symptoms (urinary urgency, urinary frequency, dysuria, hematuria, 
vaginal discharge, pelvic, pain; 100%; 6/6) 
• Result of UA (66.7%; 4/6) 
• Urine sent for culture (83.3%; 5/6) 
If yes, did the culture return back positive/negative for a UTI? 
• Other, please indicate 
Half of participants (3/6) believed the criteria should include the follow-up question--“If 
yes, did you receive a test of cure?”--for patients with a prior history of STI(s), whereas 
66.7% (4/6) believed the follow-up question should be included--“If yes, did the culture 
return back positive/negative for a UTI?”--if a urine had been sent for culture analysis. 
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 The final question in round one requested that participants make additional 
recommendations or comment about the proposed clinical guideline.  A comment to this 
question was as follows: 
Given the similar presentation of both UTI and GC/Chlamydia (STD), I do not 
feel anything other than complaints of symptoms and history of sexual activity 
should be required to test for both.  Given the prevalence of undiagnosed STD, 
ease of test, and ease of treatment, there isn’t any reason to not test every sexually 
active female.  Certainly all the rest of the history is important but should not 
prevent testing of both (who know what a patient will admit to!). 
 
Numerous studies have shown that symptomology alone is a poor predictor of and does 
not adequately differentiate between the presence and/or absence of an STI or UTI.  In 
fact, research indicated the only factor found to be predictive of a positive STI result was 
history of greater than one sexual partner within the last 12 months (Shapiro et al., 2005).  
Therefore, as expressed by the comment above, research supports testing for both 
chlamydia and gonorrhea in female patients with a history of sexual activity especially 
given the current and rising rate of undiagnosed STIs.   
 Conclusions drawn from round one of the Delphi questionnaire reiterated and 
supported benefits that could be garnered from creation and implementation of a clinical 
guideline.  Incorporating participant responses from round one of the Delphi method and 
published screening recommendations, a draft of the guideline was completed.  The 
STI/UTI Urinalysis Clinical Practice Guideline was divided into the following sections:  
• Overview  
• 2014 U.S. Preventive Services Task Force (USPSTF) Screening 
Recommendations for Chlamydia and Gonorrhea  
• Assessment of Risk  
• Clinical Manifestations and Testing  
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• Collection of Urine 
• Results of Initial Urinalysis  
• Urine Culture  
• Suggested Algorithm    
Results and Outcome Statements:  
Round Two Delphi Questionnaire 
 Round two of the Delphi questionnaire included 10 questions that provided an 
overview of some of the responses collected from round one of the Delphi questionnaire 
in addition to statistical data collected from the retrospective chart reviews.  As stated 
previously, consensus defined by this DNP project was a statistical score of 0.70 or 
greater for each question, representing majority agreement among participants for each 
component of the clinical guideline.   
 Each question in round two resulted in 100% (4/4) consensus.  All agreed the 
current adherence to current STI screening recommendations was too low (question one); 
providers were surprised by results of the chart review, which revealed the percentage of 
negative urine cultures for female patients diagnosed and treated for a UTI (question 
three).  Questions 6 through 10 required the participants to evaluate the draft of the 
clinical guideline.  Question six reviewed risk factors to be included within the 
Assessment of Risk section; providers did not believe any additional risk factors should 
be contained in the guideline.  Question seven had the participants review the outlined 
Clinical Manifestations and Testing portions of the guideline.  Although all providers 




I understand need for two urine specimens however what do you do with the 
“same-day” patient which is the vast majority of UTI patients?  How would you 
propose getting a “dirty” urine on a patient who awoke with s/s and then is on 
your schedule the same afternoon? 
 
Organizational education regarding collection requirements for a “dirty urine” 
sample would be paramount in ensuring patients come prepared to their office visit ready 
to provide two urine samples.  Outlined within the body of the guideline were steps and 
information necessary to properly collect dirty urine samples.  Patients would need to be 
instructed to refrain from voiding for a minimum one hour period prior to their scheduled 
appointment (Elliot Hospital Laboratory, 2014).  As long as patients are made aware of 
this requirement prior to their appointment, the one hour no-void requisite should not be a 
hindrance in completing STI testing.        
 Questions eight and nine asked participants to review the remaining sections 
outlining suggested parameters for a positive UA result and parameters for ordering 
additional testing such as urine cultures and STI testing.  All providers approved of the 
outlined parameters and no additional comments were offered.  Although the initial draft 
of the clinical guideline had received 100% provider consensus, some modifications were 
made by the author to make the final guideline more comprehensive.  For example, an 
additional section was added to the guideline listing the most recent recommended 
pharmaceutical regimens and alternative regimens in treatment of chlamydia and 
gonorrhea infections.  A full version of the STI/UTI Urinalysis Clinical Practice 
Guideline can be found in Appendix G.      
Objective Three 
 Objective three and the final objective of this DNP capstone project was plan for 
implementation of the STI/UTI Urinalysis Clinical Practice Guideline into practice at 
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Peak Health Family Medicine.  Although physical implementation of the guideline was 
not a component of this project, necessary resources were provided to the organization 
for implementation at a later date.  Objective three was accomplished by developing the 
clinical guideline utilizing information gathered from the literature review, current 
published guidelines for both STIs and UTIs, and responses collected from the Delphi 
questionnaires.  Participant responses from rounds one and two of the Delphi method 
provided needed consensus in successful creation of said guideline.  As discussed and 
analyzed under the results section of objective two, questionnaire replies provided the 
structural foundation in achieving objective three. 
Key Facilitators and Key Barriers to Project Objectives 
Key Facilitators 
 Successful and effective completion of this DNP capstone project could be 
attributed to the following key factors: availability and use of the eMDs EMR platform 
and provider engagement and interest in capstone objectives at Peak Health Family 
Medicine.  It would not have been possible for the author to complete the two-part 
retrospective study without use of the EMR as it aided in efficient gathering of 
information, particularly with regard to the four-year ICD-9 and ICD-10 (CDC, 2017) 
diagnoses analysis.  As stated previously, individual chart reviews required a 
considerable amount of time; a four-year review of every patient chart for every provider 
would not have been feasible within the timeline specified in completion of this project.  
Inspiration for this DNP capstone project arose from an article displayed in the office of 
one of the providers at Peak Health Family Medicine.  It was advantageous to the author 
to have chosen a topic already an area of interest to some of the providers within the 
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organization.  Successful facilitation of this project was greatly aided by the involvement 
and desire of all providers at Peak Health Family Medicine in improving their current 
healthcare practice surrounding STI and UTI screening and diagnosis. 
 Key stakeholders of this DNP capstone project primarily included healthcare 
providers at Peak Health Family Medicine and female patients (established and new) who 
visit the organization seeking treatment for UTI symptoms.  The STI/UTI Urinalysis 
Clinical Practice Guideline will facilitate and support providers in distinguishing between 
patients who might require additional testing when presenting to the office with UTI 
complaints.  Early diagnosis of STIs such as chlamydia and gonorrhea can only occur if 
appropriate testing is performed.  The negative impact and unintended consequences of 
untreated STIs are significant; therefore, it is imperative that providers aptly evaluate 
female patients who would benefit from STI testing. 
Key Barriers  
 Barriers to project objectives included limitations of the EMR in completion of 
the retrospective study, organizational growth of Peak Health Family Medicine and 
associated incidence in UTI patient visits between 2013 and 2016, and a relatively small 
sample size for round one of the Delphi questionnaire.  To assess the applicability of the 
STI/UTI Urinalysis Clinical Practice Guideline at Peak Health Family Medicine, an 
evaluation of UTI diagnostic frequency was performed.  However, the EMR could not 
separate total yearly ICD code frequency between genders.  Therefore, although it was 
beneficial to see the trending nature of UTI diagnoses year after year within this practice, 
it could not be quantified what diagnoses were linked with male patient visits and what 
diagnoses were linked with female office visits.  Although women tend to be 
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disproportionately affected by UTIs, the author could not state with certainty that the 
majority of UTI diagnoses made were for Peak Health Family Medicine’s female patient 
population.     
 The four-year ICD-9 and ICD-10 (CDC, 2017) diagnoses analysis indicated Peak 
Health Family Medicine saw an increasing number of patients each successive year for 
UTIs.  However, the organization had two medical providers in 2013, whereas four 
medical providers were employed at the organization at the end of 2016.  Therefore, it 
would have been beneficial to have had the capability to delineate between each 
individual provider each year to appreciate whether the increasing numbers of UTI 
associated diagnoses were correlated with patient demographics or due to the practice 
treating more patients each year with the addition of providers.  As the purpose of this 
portion of the retrospective chart review was to provide Peak Health Family Medicine 
with an indication about general applicability and utility of a clinical guideline for future 
practice, the delineation between providers was not required but would have provided 
more comprehensive and detailed information. 
 Utilization and effectiveness of the Delphi method through a series of 
questionnaires was founded upon the knowledge that study subjects were experts within 
their field and their responses and participation contributed positively to the ascribed 
objectives.  A barrier to implementation of round one of the Delphi questionnaire was the 
relatively small number of participants.  The author had hoped to garner participation 
from healthcare providers at organizations exposed to STIs more frequently such as 
Planned Parenthood; however, round one questionnaires were not returned to the author 
from requested study panel members.  Additionally, where large healthcare organizations 
50 
 
such as Kaiser Permanente have a multitude of providers who could be contacted easily 
through their intranet and shared e-mail groups, Peak Health Family Medicine is a 
private, primary care practice with a limited amount of staff.  It was difficult to obtain a 
large listing of healthcare providers, contributing significantly to the small number of 
study subjects ultimately requested to participate in round one of the Delphi method. 
 The Delphi method and associated Delphi questionnaire(s) were determined by 
the author to be the most efficient and effective means to collect opinions and attitudes of 
multiple providers who practice in a variety of settings and healthcare disciplines.  
Structure of the Delphi method allows for collection of both quantitative and qualitative 
data and could be adapted to changing objectives.  An added limitation or barrier was the 
relative ease of invited individuals to decline participation.  Similarly, the potential for 
bias in panel providers’ responses existed as opinions could differ between individuals 
who chose to participate versus individuals who declined participation. 
Unintended Consequences 
 An unintended positive consequence of this DNP capstone project was the 
overwhelming support and provider interest in actually implementing the guideline in the 
future.  Due to time constraints in completion of this capstone project, physical 
implementation and post-implementation evaluation would not have been a realistic 
component of this project.  However, the author was not certain whether Peak Health 
Family Medicine would choose to trial the clinical guideline.  Based upon discussions 
with medical providers at this organization, it appears there is a considerable amount of 
interest in trialing the guideline in day-to-day practice and future use of said guideline is 













 As depicted and supported by the literature review and responses gathered from 
the Delphi questionnaires, STI screening and evaluation have been variable and 
inconsistent.  Lack of appropriate STI diagnosis might result in prescribing inadequate 
and incorrect pharmaceutical therapy, potential spread the disease(s) to other individuals, 
and predisposes the individual to reproductive and gynecological complications in the 
future.  The following recommendations and implications for practice serve to address 
the problem statement of this DNP capstone project--that diagnosis of either an STI or 
UTI can be difficult as presenting and associated symptoms such as complaints of 
urgency, frequency, and/or dysuria are similar in nature (Tomas et al., 2015).  It is 
essential for healthcare providers to have the necessary tools and resources available to 
appropriately diagnose, differentiate, and treat STIs and UTIs to prevent the negative 
health impact of untreated chlamydia and gonorrheal infections.  Accordingly, 
development of the STI/UTI Urinalysis Clinical Practice Guideline was created to 
address this deficit in practice and aide providers at Peak Health Family Medicine in 





Recommendations for Guideline Implementation within 
the Framework of the Organization’s Strategic Plan 
  
 Phase four, the final phase of this DNP capstone project, would ultimately entail 
implementation of the guideline into daily practice at Peak Health Family Medicine and 
outcomes evaluation post-guideline implementation.  Based upon results garnered from 
completion of the retrospective study and information assembled from the Delphi 
questionnaires, the author recommends the project move forward.  The timeframe in 
which to physically implement the guideline has been left to the discretion of Peak Health 
Family Medicine’s healthcare providers. 
 To increase the likelihood of successful guideline implementation, the author 
advises the following steps be taken prior to integrating said guideline into routine 
practice.  First, it would be prudent to provide education surrounding the guideline to all 
applicable staff members.  An educational seminar about the guideline and each 
individual’s role could be provided during the weekly staff meeting.  Staff members to 
include in the educational training would be the receptionists, medical assistants, and 
registered nurse.  It would be the responsibility of the receptionists to be mindful of the 
fact that two urine samples could potentially be required for female patients who call to 
schedule an appointment for complaint of UTI symptoms.  To collect a dirty urine 
sample, the patient cannot urinate for one hour (at minimum) prior to urine collection.  
This information would need to be communicated clearly to the patient.  Each medical 
assistant would need to be aware of varying collection requirements of a dirty versus 
clean urine sample and be cognizant to keep each sample separate to prevent cross-
contamination.  The registered nurse would be expected to perform the same duties as the 
medical assistants when needed.   
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 Once it has been ascertained that all staff members have access to and knowledge 
of the STI/UTI Urinalysis Clinical Practice Guideline, a specific implementation date and 
trial timeframe should be chosen.  As with any other patient visit, it would be up to the 
provider to determine and order the necessary tests.  However, providers should be 
encouraged to follow the algorithm provided by the guideline (for at least the trial 
timeframe).  If adherence to the guideline is low or sporadic, evaluation of the guideline 
would not be of any benefit and objectives of performing a post-implementation 
evaluation would be lost.   
Recommendations for Guideline Evaluation 
 Post-implementation evaluation should be conducted once the trial timeframe has 
ended.  Based upon current job responsibilities of staff members at Peak Health Family 
Medicine, the registered nurse would be best suited to take responsibility in performing 
this component of phase four.  As the author already conducted a three-month 
retrospective chart review during phase two of this DNP capstone project, it is suggested 
that three months be the minimum duration for the trial timeframe.  Upon completion of 
the trial, another chart review should be completed mirroring the same parameters 
outlined in Chapter IV.  A results comparison of the two studies would be simple and 
would provide the practice with a relatively clear picture about the utility of the 
guideline.  Additional evaluation that would be beneficial would be a questionnaire 
concerning provider perception of the guideline, identification of any changes or updates 
needed to the guideline, and appraisal of any unexpected (positive or negative) outcomes.       
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Ongoing Activities or Evaluations Outside the Scope 
of the Doctor of Nursing Practice Project 
 
This DNP capstone project lightly touched upon the unintended consequence in 
the rate of STI screening after the USPSTF updated their cervical cancer screening 
recommendations in women in 2012.  Screening for chlamydia and gonorrhea was found 
to have decreased by 50% since release and publication of the new guidelines (Bogler et 
al., 2015).  The discordant screening recommendation for cervical cancer and 
chlamydia/gonorrhea emphasizes the importance and need for primary care providers in 
routinely addressing sexual health during other patient care visits.  Ease of urine-based 
testing in diagnosis of chlamydia and gonorrhea should increase the frequency of 
screening for these diseases, especially for young female patients 15 to 25 years of age.  
Discussions with patients regarding STIs can be uncomfortable; however, if discussions 
begin at an early age and become a normalized part of patient visit questions, it is more 
likely that yearly STI screening will be performed.   
Personal Goals and Contribution to Advanced 
Practice Nursing 
 
The role of an Advanced Practice Nurse continues to progress and develop with 
the dynamic nature of the current healthcare system.  The field of advanced practice 
nursing has morphed to meet the demands of medicine by providing evidence-based 
practice, emphasizing nursing leadership, and facilitating quality improvement projects.  
Contributions to advanced practice nursing can vary greatly and come in many forms; 
simple changes can sometimes have a considerable impact.  Dedication to this DNP 
capstone project was the author’s hope of effecting positive change and cultivating not 
only the current health of young female patients but also maximizing their future health.  
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A personal goal of the author was to effectively culminate skills and knowledge learned 
through the DNP program and successfully harness the acquired tools and processes 
beyond the scope of assigned coursework.  Attainment of personal goals and successful 
completion of this DNP capstone project mandated the author step firmly into a 
leadership role in demonstrating competency and readiness to advance into the position 
as a Doctor of Nursing Practice.    
Five Criteria for Executing a Successful Doctor of  
Nursing Practice Final Project 
 
With the emergence and recent proliferation of Doctor of Nursing Practice 
programs across the country, there arose discussion regarding potential variability and 
expectations amongst the assorted DNP programs.  As stated by the American 
Association of Colleges of Nursing (AACN; 2006), the fundamental purpose of DNP 
programs “should be to produce nurses that are uniquely prepared to bridge the gap 
between the discovery of new knowledge and the scholarship of translation, application, 
and integration of this new knowledge in practice” (Waldrop, Caruso, Fuchs, & Hypes, 
2014, p. 300).  To achieve or ensure each program was meeting expectations, the AACN 
Essentials of Doctoral Education in Advanced Nursing Practice were provided as an 
instrument to comprehensively evaluate DNP capstone projects.  Waldrop et al. (2014) 
summarized the AACN instrument and developed the acronym EC as PIE (E = Enhances; 
C = Culmination; P = Partnerships; I = Implements; E = Evaluates) that outlines five 
essential criteria required for all completed DNP capstone projects (see Figure 8).  Each 
of the five criteria “must be present and come together to form one complete ‘pie’ 
representing evidence-based practice that is robust and innovative, culminating in a 




Figure 8.  Five criteria for executing a successful Doctor of Nursing Practice final project 
(Waldrop et al., 2014). 
 
  
The first of the five criteria or pieces of the pie stipulates the DNP capstone 
project must enhance health.  Enhancement of health can be achieved through 
improvement in healthcare policy, health outcomes, or practice outcomes (Waldrop et al., 
2014).  The explicit purpose of this capstone project was to improve diagnostic 
differentiation between STIs and UTIs in female patients within a primary care practice 
setting.  By decreasing the frequency of misdiagnosed chlamydial and gonorrheal 
infections, female patients should not only be more appropriately treated but treated 
sooner corresponding to both better health and practice outcomes.   
Criteria two is evidence or demonstration of the culmination of practice inquiry.  
The culmination of practice investigation or inquiry is specified as the ability or the 
purposeful execution of the DNP student to attain expert knowledge about a specific 








clinical care setting (Waldrop et al., 2014).  This criterion was accomplished during phase 
one of this DNP capstone project by conducting a comprehensive literature review that 
evaluated past and current issues surrounding misdiagnosis of STIs and UTIs.  In addition 
to the literature review, feasibility and necessity for practice change were assessed to 
gauge true applicability of such change within the identified family practice care setting.   
Criteria three necessitates the formation of partnerships; through engagement in 
partnerships with members of an interdisciplinary team, the DNP student collaborates and 
more effectively achieves the stated goals and purpose of the capstone project (Waldrop 
et al., 2014).  Peak Health Family Medicine is composed of medical assistants, a 
registered nurse, PAs, an NP, and an MD all working together as an interdisciplinary 
team to coordinate care for each and every patient.  Successfully developing the clinical 
practice guideline required active involvement and participation from each of the medical 
providers at Peak Health Family Medicine including the DNP student.  Implementation 
of the guideline (in the future) will require not only the medical providers but all 
members of the team working together to ensure the guideline is effectively and correctly 
instigated and utilized.       
Implement/apply/translate evidence is the cornerstone of criteria four.  Criteria 
four is demonstrated by thoughtful evaluation of evidence and translation or application 
of such evidence into meaningful use (Waldrop et al., 2014).  Evaluation of evidence for 
this capstone project was completed during the literature review.  Information gathered 
from the various studies indicated the need for a change in practice to aid medical 
providers in differentiating STI and UTI diagnoses.  In addition, the development of the 
clinical practice guideline required valuation and application of a multitude of sources 
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including national screening guidelines published by the USPSTF (2016) and CDC 
(2016) in addition to responses collected from the Delphi questionnaires.   
The fifth and final criterion for a successful DNP project is evaluation of 
healthcare or practice outcomes.  Evaluation of outcome measures are not limited to but 
might include measures such as financial cost, accessibility of care, quality improvement, 
and/or consequences of a healthcare policy (Waldrop et al., 2014).  Due to time 
constraints, this DNP capstone project did not implement the clinical guideline into 
practice.  However, several outcome measures were discussed and advised for Peak 
Health Family Medicine in order to calculate and value the implications of said guideline 
in accordance with day-to-day practice within their organization.               
Summary 
Continued rise of chlamydia and gonorrhea infections in young females has been 
attributed to a variety of causes; however, a significant contributing factor is the 
misdiagnosis of these disease processes for urinary tract infections.  Overlapping 
symptomology of urinary tract infections and sexually transmitted infections has 
perpetuated this problem.  Considerable amount of evidence has demonstrated a 
substantial percentage of female patients will test positive for a sexually transmitted 
infection when presenting with symptoms commonly associated with a UTI (Mehta et al., 
2001; Shapiro et al., 2005; Todd et al., 2001).  The CDC (2016) and USPSTF (2016) 
recommend annual screening for chlamydia and gonorrhea in female patients 15 to 25 
years of age and in females older than 25 years who have an identified risk factor.  
Development of the STI/UTI Urinalysis Clinical Practice Guideline was created to 
facilitate comprehensive preventative care through integration of evidence-based 
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literature.  Proper guideline utilization will enhance STI screening and diagnosis in 
adolescent females and women with identified high-risk factors.  Early diagnosis and 
treatment of STIs within this population will effectively decrease or prevent future 
reproductive and gynecological consequences due to untreated chlamydia and/or 
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Phase One: Delphi Study Round One Questionnaire 
 
1. What is your current career title/role? (You may indicate more than one if applicable) 
MD _____DO _____APN _____PA _____Other, please indicate __________ 
 
2. In which discipline do you primarily work? 
Family Medicine _____ 
Internal Medicine _____ 
Pediatric Medicine _____ 
OB/GYN _____ 
Other, please indicate __________ 
 





4. Do you feel providers at your organization follow current recommendations for 
Sexually Transmitted Infection (STI) screening & diagnosis? Specifically, screening for 
Chlamydia trachomatis and Neisseria gonorrhoeae infections in female patients? 
Is always followed by providers in my discipline _____ 
Followed by some providers in my discipline _____ 
Followed by some providers in another discipline _____ (which one) __________ 
Rarely followed _____ 
Should not be followed _____ 
Should be followed more frequently than is currently _____ 
Other, please indicate __________ 
5. Do you feel providers at your organization follow current recommendations for 
Urinary Tract Infection (UTI) screening & diagnosis? 
Is always followed by providers in my discipline _____ 
Followed by some providers in my discipline _____ 
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Followed by some providers in another discipline _____ (which one) __________ 
Rarely followed _____ 
Should not be followed _____ 
Should be followed more frequently than is currently _____ 
Other, please indicate __________ 
 




7. Do you feel patients are being routinely screened for STI(s) at your organization when 




8. How often do you believe female patients are being tested at your organization for 
chlamydia and gonorrhea infections when presenting with a chief complaint otherwise 
indicative of a UTI? 
90% - 100% _____   50% - 59% _____  Less than 20% _____ 
80% - 89% _____   40% - 49% _____ 
70% - 79% _____   30% - 39% _____ 
60 % - 69% _____   20% - 29% _____ 
 
9. If a clinical guideline were available to you and your organization for improved 
screening of female patients at higher risk for chlamydia and gonorrhea infections, do 




10. What do you believe should be covered in an STI/UTI Urinalyses Guideline? *The 





_____ Current form of contraception 
_____ Number of past sexual partners within the past year 
_____ New sexual partner 
_____ History of prior sexually transmitted infection(s) 
 _____ If yes, did you receive a test of cure? 
_____ Substance Use (alcohol, tobacco, recreational drugs) 
_____ Sex in exchange for money or drugs 
_____ Current symptoms (urinary urgency, urinary frequency, dysuria, hematuria, 
vaginal     discharge, pelvic pain) 
_____ Result of UA 
_____ Urine sent for culture? 
 _____ If yes, did the culture return back positive/negative for a UTI? 
 
Other, please indicate __________ 
 
 




















INFORMED CONSENT FORM FOR HUMAN  




CONSENT FORM FOR HUMAN PARTICIPATION IN RESEARCH 
UNIVERSITY OF NORTHERN COLORADO 
PEAK HEALTH FAMILY MEDICINE 
INFORMED CONSENT – NO SIGNATURE DOCUMENT 
Project Title: Sexually Transmitted Infection or Urinary Tract Infection? Misdiagnosis of 
Chlamydia Trachomatis and Neisseria Gonorrhoeae Infections in Primary Care Practice 
Student Researcher: Bethany M. Summers, BSN, RN, BA, DNP-S 
Research Advisor: Kathleen N. Dunemn, PhD, APRN, CNM, School of Nursing 
Co-Research Advisor: Vicki Wilson, PhD, MS, RN, School of Nursing 
Committee Member: Jill A. Quigley, M.D. 
 
Expert Consensus: A Delphi Study 
The purpose of the following Doctor of Nursing Practice Capstone Project is to develop 
an evidence-based clinical guideline for improved diagnostic screening methods for 
diagnosis of chlamydial and gonorrheal infections in females who present with 
symptomatic complaints otherwise suggestive of a urinary tract infection.  Evaluation and 
assessment of current screening practices for Sexually Transmitted Infections (STIs) and 
Urinary Tract Infections (UTIs) by medical providers at Peak Health Family Medicine 
will be conducted.  In addition to Peak Health Family Medicine, medical providers within 
other healthcare organizations inside the Denver Metro Area will also be requested to 
participate.   
The Delphi Method is a structured communication tool or technique that utilizes a 
questionnaire format to survey a panel of experts (within the field of study under 
investigation), using two or more rounds of questioning.  Information gathered from the 
Literature Review regarding misdiagnosis of STIs and UTIs was used in development of 
the first round of questions.  The first round of questions will also relay general 
information regarding current recommendations from both the United States Preventive 
Services Task Force (USPSTF) and the Centers for Disease Control and Prevention 
(CDC) in diagnostic evaluation of both STIs and UTIs.  Responses gathered from round 
one will be used in development of the clinical practice guideline.  A second round of 
questions will then be conducted in evaluation of the proposed guideline in applicability 
to practice at Peak Health Family Medicine.  Responses gathered from the first round of 
questioning will be anonymously shared with the participants during the second round.   
The Delphi Method, originally developed in the 1950’s, has been used in healthcare, as 
well as other industries and is of value when there is uncertainly or lack of empirical 
knowledge to achieve general consensus.  It is an effective tool to assist in protocol 
changes as it requires integration of expert review and opinion even in the presence of 
disagreement.  It is anticipated that two rounds will be necessary for completion of this 
capstone project.  All Delphi surveys will be sent and returned electronically with a 
private e-mail account only accessible by the DNP student.  It is estimated that each 
78 
 
participant will spend approximately 15-20 minutes in completion of survey questions 
within each round of the Delphi process. 
Participation is voluntary and all responses collected from the surveys will be kept 
anonymous.  The data collected will be kept on a password protected thumb drive that 
will have restricted accessibility; information collected will be available only to the DNP 
student and her Research Advisor.  There are no anticipated risks to participants. This is a 
quality improvement project to improve the evaluation, differentiation, and diagnosis of 
STIs versus UTIs. 
You may decide not to participate in this study and if you begin participation you may 
still decide to stop and withdraw at any time. Your decision will be respected and will not 
result in a loss of benefits to which you are otherwise entitled.  If you have any questions, 
please contact one of the undersigned. 
Having read the above document and having had an opportunity to ask any questions, 
please complete the questionnaire “Phase One: Delphi Study Round One Questionnaire” 
if you would like to participate in this research.  By completing and returning the Delphi 
questionnaire, it will be assumed that you have communicated consent in participation.  
Please print and keep this form for future reference.  Please return the completed survey 
to BethanyMSummers@gmail.com. 
If you have any concerns about your selection or treatment as a research participant, 
please contact Sherry May, IRB Administrator, Office of Sponsored Programs, Kepner 
Hall, University of Northern Colorado, Greeley, CO 80639; Phone 970-351-1910. 
This informed consent will be e-mailed and accompany each round of the study. 
 
Student Researcher: Bethany M. Summers, BSN, RN, DNP-S 
 
Research Advisor: Kathleen N. Dunemn, PhD, APRN, CNM  
E-mail: Kathleen.Dunemn@unco.edu  
Phone: (970) 351-3081/ (303) 649-5581 
 
Co-Research Advisor: Vicki Wilson, PhD, MS, RN 
E-mail: Vicki.Wilson@unco.edu 
Phone: (970) 351-1295 
 
Committee Member: Jill A. Quigley, M.D. 
Address: Peak Health Family Medicine 
    10901 West Toller Drive, Suite 100 
    Littleton, CO 80127 























Phase Two: Delphi Study Round Two Questionnaire 
Thank you for your participation in the Delphi Study Round Two Questionnaire.  The 
purpose of the Phase Two: Delphi Study Round Two Questionnaire is to build consensus 
around the proposed Clinical Practice Guideline for use by Peak Health Family Medicine.  
The objective of the proposed Clinical Practice Guideline is to assist in the differentiation 
between a Sexually Transmitted Infection (STI), specifically infection with Chlamydia 
trachomatis and/or Neisseria gonorrhoeae, and a Urinary Tract Infection (UTI) in female 
patients who present with symptom complaints indicative of a UTI. 
A retrospective chart review was conducted reviewing Peak Health Family Medicine’s 
electronic medical record (EMR) of female patient charts from October 1, 2016 through 
December 31, 2016.  Patient charts were included if (1) the patient was female, (2) 
between 15-65 years of age, and (3) chief complaint was suggestive of a UTI.  
Additionally, a four year retrospective study (January 1, 2013 – December 31, 2016) was 
completed evaluating the frequency of ICD 9 and ICD 10 diagnoses codes for UTI, 
chlamydia and gonorrhea.  Information gathered from these two studies in addition to 
responses from the Phase One: Delphi Study Round One Questionnaire was used in 
development of the proposed Clinical Practice Guideline.  Responses from the Delphi 
Study Round One Questionnaire included medical providers from NextCare Urgent Care, 
Kaiser Permanente, and Peak Health Family Medicine.     
 
Please respond to the following questions: 
1. 50% of participants responded that current recommendations for STI screening & 
diagnosis (specifically screening for Chlamydia trachomatis and Neisseria gonorrhoeae 
infections in female patients) is always followed by providers in my discipline.   33% of 
respondents felt that current recommendations should be followed more frequently than is 












2. The majority of respondents felt that current recommendations for UTI screening & 
diagnosis is always followed by providers in my discipline. Would you agree that the 
current recommendation as published by UpToDate is a reasonable guideline in the 
screening and diagnosis for UTI in women? 
Yes _____ 
No _____ 





3. Of the 41 female patients who were seen at Peak Health Family Medicine between 
October 1, 2016 and December 31, 2016 for UTI complaints, 78.0% (32) of patients were 
diagnosed and prescribed antibiotic therapy in treatment of a UTI.  Of the 32 patients 
treated for a UTI, results of the subsequent urine culture were negative for 46.8% (15) of 
those started on antibiotic therapy.  Are you surprised by this finding? 
Yes, I assumed the percentage of positive culture results would be higher _____ 
Yes, I assumed the percentage of positive culture results would be lower _____ 
No, the percentage of negative urine cultures is to be expected _____ 













4. More than half of participants responded that they did not feel patients are being 
adequately screened for STIs at their organization.  Additionally, only 33% of 
respondents believed that patients were being routinely screened for STI(s) when 
presenting with a chief complaint otherwise indicative of a UTI.  Would you agree that a 
Clinical Practice Guideline would increase the frequency of such screening? 
Yes _____ 
No _____ 





5. When asked about the frequency or percentage of female patients being tested for 
chlamydia and gonorrhea infections when presenting with a chief complaint otherwise 
indicative of a UTI, the majority of participants responded with an estimated frequency of 
less than 20%.  Results of the chart review revealed that patients were tested for chlamydia 
and/or gonorrhea 2.4% of the time.  Based upon this statistic alone, would you agree that 
testing for chlamydia and gonorrhea needs to occur more often? 
Yes _____ 
No _____  













6. Based upon the proposed Clinical Practice Guideline, are there any additional risk factors 
that should be included in the Assessment of Risk? 
Yes _____ 
If yes, please specify ______________________________________________________ 
No _____ 





7. Based upon the proposed Clinical Practice Guideline, do you agree with the outlined 
Clinical Manifestations and Testing guideline? 
Yes _____ 
No _____ 
If no, please specify _______________________________________________________ 





8. Based upon the proposed Clinical Practice Guideline, do you agree with the included 
parameters for a positive UA result? 
Yes _____ 
No _____ 
If no, please specify _______________________________________________________ 






9. Based upon the proposed Clinical Practice Guideline, do you agree with the included 
parameters for additional testing i.e. urine culture and STI testing? 
Yes _____ 
No _____ 
If no, please specify _______________________________________________________ 





10. Are there any other comments you would like to make about the proposed Clinical 
Practice Guideline? 
Yes _____ 
If yes, please specify ______________________________________________________ 
No _____ 





Thank you for your participation in completion of the above questionnaire.  If you have 















































































Abdominal Pain, Hematuria, Nausea,  
Urinary Frequency, Dysuria 
Urgency, Urinary Frequency, Dysuria 
Abdominal Pain, Chills, Nausea, Urgency 
Nausea, Urgency, Urinary Frequency 
Abdominal Pain, Hematuria, Nausea, Urgency, 
Urinary Frequency, Dysuria 
Hematuria, Urgency, Urinary Frequency 
N/A 
Abdominal Pain, Urgency, Urinary Frequency, 
Dysuria, Vaginal Irritation 
Abdominal Pain, Chills, Nausea, Urgency,  
Urinary Frequency, Vaginal Discharge 
Dysuria 
Dysuria 
Dyspareunia, Dysuria, Vaginal Discharge, 
Vaginal Itching 







Blood in Urine: Positive 
Not Completed - AZO 
Blood in Urine: Positive;  
Protein Urine: 2+; Leukocytes: 1+ 
Blood in Urine: Positive;  
Protein Urine: Trace 
Blood in Urine: Positive;  
Leukocytes: 2+ 
Blood in Urine: Positive;  
Protein Urine: 2+; Leukocytes: 4+ 
Negative 







Blood in Urine: Positive;  
Leukocytes: 1+ 
Blood in Urine: Positive;  



























































































































Flank Pain, Nausea, Urgency, Urinary Frequency 
Abdominal Pain, Fever, Urinary Frequency 
Dysuria 
Abdominal Pain, Fever, Hematuria 
Urinary Frequency, Dysuria 
Abdominal Pain, Flank Pain, Odor 
Flank Pain, Hesitancy, Urgency,  
Urinary Frequency 
N/A 
Hematuria, Urgency, Urinary Frequency 
Dysuria 
Dysuria, Urgency 
Flank Pain, Urgency, Urinary Frequency 
Abdominal Pain, Dysuria 
Abdominal Pain, Hematuria, Nausea,  
Urinary Frequency, Dysuria 
Abdominal Pain, Flank Pain, Hematuria,  
Urgency, Urinary Frequency, Dysuria 
 
Blood in Urine: Positive;  
Protein Urine: 2+; Leukocytes: 4+ 
Blood in Urine: Positive; 
Leukocytes: 2+ 
Negative 
Blood in Urine: Positive 
Leukocytes: 2+ 
Blood in Urine: Positive; 
Protein Urine: 2+; Nitrite: Positive; Leukocytes: 4+ 
Blood in Urine: Positive 
Negative 
Leukocytes: 1+ 
Protein Urine: Trace; Leukocytes: 2+ 
Blood in Urine: Positive;  
Leukocytes: 3+ 
Blood in Urine: Positive;  
Protein Urine: 2+ 
Nitrite: Positive 
Blood in Urine: Positive;  
Protein Urine: 1+ 
Blood in Urine: Positive;  





























































































Cloudy Urine, Pelvic Pain, Hematuria 
Abdominal Pain, Urgency, Urinary Frequency, 
Dysuria 
Abdominal Pain, Chills, Urinary Frequency,  
Urgency 
Cloudy Urine, Pelvic Pain, Hematuria 
Chills, Fever, Flank Pain, Hematuria, Nausea, 
Urinary Frequency 
Urgency, Urinary Frequency, Dysuria 
Discomfort 
Dysuria, Urgency, Urinary Frequency, Chills,  
Flank Pain, Hesitancy, Urinary Incontinence 
 
Negative 
Ketones: 1+; Leukocytes: 2+  
Glucose: 3+ 
Nitrite: Positive; Leukocytes: 1+ 


































































PEAK HEALTH FAMILY MEDICINE 
CLINICAL PRACTICE GUIDELINE 
 
 
TITLE: Sexually Transmitted Infection (Chlamydia trachomatis/Neisseria 
gonorrhoeae) or Urinary Tract Infection (Acute Cystitis) Urinalysis Clinical 
Practice Guideline 
Reviewed: June, 2017 
Target Population: All female patients between 15 to 25 years of age and female 
patients older than 25 years of age with at least one identified risk factor.    
Rationale: The following guideline will assist in the differentiation between a Sexually 
Transmitted Infection (STI), specifically infection with Chlamydia trachomatis and/or 
Neisseria gonorrhoeae, and a Urinary Tract Infection (UTI).   
Author: Bethany Mee Yeong Summers, BSN, RN, DNP-S 
 
1. Overview 
Diagnosis of either an STI or UTI can be difficult as presenting and associated symptoms 
such as complaint of urgency, frequency, and/or dysuria are similar in nature (Tomas, 
Getman, Donskey, & Hecker, 2015).  In addition, the results of a urinalysis (UA) may 
present overlapping abnormalities; most commonly pyuria and positive leukocyte 
esterase (Tomas et al., 2015).   
 
A retrospective study of five family practices found that screening for gonorrhea and 
chlamydia decreased by 50% since publication of the new cervical cancer screening 
guidelines by the U.S. Preventive Services Task Force (USPSTF) in 2012 (Bogler et al., 
2015).  Therefore, primary care practices and providers need to maximize other 
opportunities and patient care visits to ensure that sexual health and STI screening are 
completed, especially within the high-risk, young, female patient population.   
Due to the frequent asymptomatic presentation of chlamydial infections in women, 
universal screening has been suggested as the most effective means in disease detection; 
however, the cost of such practice is unrealistic.  It has therefore been recommended that 
infection screening be selectively completed based upon organizational parameters or that 
women be treated empirically using defined criteria addressing factors such as an 
individual’s age, sexual behavior, and/or symptomatic complaint(s) at time of visit 
(Marrazzo et al., 1997). 
Urine-based testing for diagnosis of chlamydia and gonorrhea using nucleic acid 
amplification tests (NAATs) has been found to be both sensitive and specific; ease and 
availability of urine-based testing allows for increased STI testing and effectively screens 
disease presence in asymptomatic individuals otherwise not pursuing healthcare services 
(Jones, Knaup, Hayes, & Stoner, 2000).     
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2. 2014 U.S. Preventive Services Task Force (USPSTF) Screening Recommendations 
for Chlamydia and Gonorrhea 















The USPSTF recommends 
screening for chlamydia in 
sexually active women age 
24 years and younger and in 
older women who are at 











The USPSTF recommends 
screening for gonorrhea in 
sexually active women age 
24 years and younger and in 
older women who are at 








Definition: The USPSTF recommends this service. There is high certainty that the net 
benefit is moderate or there is moderate certainty that the net benefit is moderate to 
substantial. 
Suggestions for Practice: Offer or provide this service. 
3. Assessment of Risk  
If any of the risk factors listed below apply to the patient in question, the patient is 
categorized as high risk (USPSTF, 2016). 
(a) Age: Infection rates for Chlamydia and Gonorrhea are highest in sexually 
active females 20 to 24 years of age, closely followed by females 15 to 19 years of 
age. 
 (b) New sex partner 
 (c) More than one sex partner 
 (d) Sex partner with concurrent partners 
 (e) Sex partner who has an STI 
 (f) Exchanging sex for money or drugs 




4. Clinical Manifestations & Testing 
A. Order a “dirty urine” sample and a clean catch urinalysis (UA) for all female 
patients between 15 to 25 years of age. 
 
B. Order a dirty urine sample and a clean catch UA for all female patients older 
than 25 years of age with one identified risk factor. 
 
C. Order a clean catch urinalysis (UA) for all female patients with any of the 
following symptoms: 
  (a) Dysuria 
  (b) Urinary frequency 
  (c) Urinary urgency 
  (d) Suprapubic pain 
  (e) Hematuria  
 
5. Collection of Urine  
  
 A. First-void or “Dirty” Urine Specimen (Elliot Hospital Laboratory, 2014),  
  For the most accurate results, instruct patient: 
  i. No urination for at minimum one hour (two hours or more is preferred)  
  prior to urine collection. 
ii. No cleansing of the urogenital/peri-urethral area prior to urine 
collection. 
  iii. Initial urine stream should be collected. 
  iv. 20-30 mL of urine should be collected. 
*Instruct patient to not overfill the container as large volumes of 
urine may cause dilution and reduce sensitivity of testing. 
  For the most accurate results, instruct staff: 
  v. Specimen container must be clearly labeled as a dirty urine sample. 
  vi. Specimen container must be clearly labeled with patient name, DOB,  
  collection date, and collection time. 
 B. Clean Catch Urine Specimen Elliot Hospital Laboratory, 2014) 
  For the most accurate results, instruct patient: 
  i. Wash hands with warm water and soap. 
  ii. Cleanse urogenital/peri-urethral area with fresh towelette. 
  iii. Begin to urinate in toilet.  
  iv. Place specimen container in urine midstream.  
  For the most accurate results, instruct staff: 
  v. Specimen container must be clearly labeled as a clean urine sample.  
  vi. Specimen container must be clearly labeled with patient name, DOB,  




6. Results of Initial Urinalysis 
 
 A. UA Positive 
 The UA is considered positive if any of the following are present: 
  (a) Leukocyte esterase 
  (b) Nitrite 
  (c) Hematuria 
           
7. Urine Culture 
 
A. If the UA is positive, send the clean catch urine sample for culture for 
identification of the causative organism and completion of antimicrobial 
susceptibility profiles. 
 
B. If the UA is negative but the history and symptoms are strongly suggestive of a 
UTI, send the clean catch urine sample for culture. 
 
C. If the UA is negative and the female patient is 15-25 years of age, send the 
clean catch urine sample for culture AND send the dirty urine sample for STI 
(chlamydia and gonorrhea) testing. 
 
D. If the UA is negative and the female patient is older than 25 years of age AND 
has one identified risk factor, send the clean catch urine sample for culture AND 



























Female 15-25 years of age
Order a “dirty urine” sample and a 
clean catch urinalysis (UA) for all 
female patients between 15 to 25 years 
of age.
Result of Initial Urinalysis
If the UA is positive, send the clean 
catch urine sample for culture for 
identification of the causative 
organism and completion of 
antimicrobial susceptibility profiles.
If the UA is negative and the female 
patient is 15-25 years of age, send 
the clean catch urine sample for 
culture AND send the dirty urine 
sample for STI testing.
Female >25 years of age
Assessment of Risk
Order a dirty urine sample and a clean 
catch UA for all female patients 25 
years and older with one identified 
risk factor.
Result of Initial Urinalysis
If the UA is positive, send the clean 
catch urine sample for culture for 
identification of the causative 
organism and completion of 
antimicrobial susceptibility profiles.
If the UA is negative but the history 
and symptoms are strongly 
suggestive of a UTI, send the clean 
catch urine sample for culture.
If the UA is negative and the female 
patient is older than 25 years of age 
AND has one identified risk factor, 
send the clean catch urine sample for 
culture AND send the dirty urine 
sample for STI testing. 
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9. Treatment  
 
 A. Chlamydia 
  a. Recommended Regimens (CDC, 2016) 
   i. Azithromycin 1 g PO in a single dose OR 
   ii. Doxycycline 100 mg PO BID X 7 days 
  b. Alternative Regimens (CDC, 2016) 
   i. Erythromycin base 500 mg PO QID X 7 days 
   ii. Erythromycin ethylsuccinate 800 mg PO QID X 7 days 
   iii. Levofloxacin 500 mg PO X 7 days 
   iv. Ofloxacin 300 mg PO BID X 7 days 
 B. Gonorrhea 
  a. Recommended Regimen (CDC, 2016) 
i. Ceftriaxone 250 mg IM in a single dose PLUS Azithromycin 1 g 
PO in a single dose 
  b. Alternative Regimens (CDC, 2016) 
i. Cefixime 400 mg PO in a single dose PLUS Azithromycin 1 g 




Centers for Disease Control and Prevention. (2016). 2015 sexually transmitted diseases 
treatment guidelines. Retrieved from https://www.cdc.gov/std/tg2015/screening-
recommendations.htm 
Elliot Hospital Laboratory. (2014). Urine collections. Retrieved from 
https://www.testmenu.com/elliothospitallaboratory/TestDirectory/SiteFile?fileNa 
 me=Urine_Collections_090113.pdf 
U.S. Preventive Services Task Force. (2016). USPSTF recommendations for STI 
screening. Retrieved from https://www.uspreventiveservicestaskforce.org/ 
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